Evolution of the burden of active hepatitis C virus infection in England from September 2015 to September 2016: a repeated cross-sectional analysis
Objective To evaluate the impact of treatment with new direct-acting antivirals (DAAs) on the prevalent hepatitis C virus (HCV) population in England.Design A repeated cross-sectional analysis.Setting Four secondary care hospitals in England.Participants Patients who, in 2015 and/or 2016, had chroni...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2019-08-01
|
| Series: | BMJ Open |
| Online Access: | https://bmjopen.bmj.com/content/9/8/e029066.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846156918077259776 |
|---|---|
| author | Jason Gordon Anna Maria Geretti Lynsey Corless Laure Lacoin Michael Hurst Nathan R Hill Richard Aspinall Yuxiang Gao-Du Liam Mistry David Mutimer |
| author_facet | Jason Gordon Anna Maria Geretti Lynsey Corless Laure Lacoin Michael Hurst Nathan R Hill Richard Aspinall Yuxiang Gao-Du Liam Mistry David Mutimer |
| author_sort | Jason Gordon |
| collection | DOAJ |
| description | Objective To evaluate the impact of treatment with new direct-acting antivirals (DAAs) on the prevalent hepatitis C virus (HCV) population in England.Design A repeated cross-sectional analysis.Setting Four secondary care hospitals in England.Participants Patients who, in 2015 and/or 2016, had chronic HCV infection and were alive were eligible, regardless of the type of HCV intervention received.Outcome measures Data including intravenous drug use (IVDU) status, HCV genotype, cirrhosis status, HCV treatment history, vital status and treatment outcomes were collected at two time points in 2015 and 2016 using electronic case report forms.Results There were 1605 and 1355 patients with active chronic HCV in 2015 and 2016, respectively. Between 2015 and 2016, the proportion of patients with current IVDU increased (10.3% vs 14.5%, respectively), while that of patients with cirrhosis (28.2% vs 22.4%) and treatment-experienced patients (31.2% vs 27.1%) decreased. Among patients whose treatment outcome was known by 2016, high cure rates were observed, with an overall sustained virological response rate of 93.2%. From 2015 to 2016, there was a progressive increase in the proportion of treated patients who were non-cirrhotic, with current IVDU and non-liver transplant recipients.Conclusions The characteristics of patients with HCV remaining in contact with specialised care evolved with a changing landscape of treatment and related health policy. With increasing access to DAAs in UK, high cure rates were achieved in the study cohort. |
| format | Article |
| id | doaj-art-e1d1c5480c894984af42044ea9126f6c |
| institution | Kabale University |
| issn | 2044-6055 |
| language | English |
| publishDate | 2019-08-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | BMJ Open |
| spelling | doaj-art-e1d1c5480c894984af42044ea9126f6c2024-11-25T16:40:08ZengBMJ Publishing GroupBMJ Open2044-60552019-08-019810.1136/bmjopen-2019-029066Evolution of the burden of active hepatitis C virus infection in England from September 2015 to September 2016: a repeated cross-sectional analysisJason Gordon0Anna Maria Geretti1Lynsey Corless2Laure Lacoin3Michael Hurst4Nathan R Hill5Richard Aspinall6Yuxiang Gao-Du7Liam Mistry8David Mutimer92 Health Economics and Outcomes Research, Cardiff, UK1 Dept. of Infectious Diseases, Fondazione PTV and University of Rome Tor Vergata, Rome, Italy6 Gastroenterology Department, Hull and East Yorkshire Hospitals NHS Trust, Hull, UKEpi-Fit, Bordeaux, Nouvelle-Aquitaine, UK2 Health Economics and Outcomes Research, Cardiff, UK1 Bristol-Myers Squibb, Uxbridge, UKGastroenterology & Hepatology, Portsmouth Hospitals NHS Trust, Portsmouth, UK6 Gastroenterology Department, Hull and East Yorkshire Hospitals NHS Trust, Hull, UK7 Liver and Hepatobiliary Unit, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK7 Liver and Hepatobiliary Unit, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UKObjective To evaluate the impact of treatment with new direct-acting antivirals (DAAs) on the prevalent hepatitis C virus (HCV) population in England.Design A repeated cross-sectional analysis.Setting Four secondary care hospitals in England.Participants Patients who, in 2015 and/or 2016, had chronic HCV infection and were alive were eligible, regardless of the type of HCV intervention received.Outcome measures Data including intravenous drug use (IVDU) status, HCV genotype, cirrhosis status, HCV treatment history, vital status and treatment outcomes were collected at two time points in 2015 and 2016 using electronic case report forms.Results There were 1605 and 1355 patients with active chronic HCV in 2015 and 2016, respectively. Between 2015 and 2016, the proportion of patients with current IVDU increased (10.3% vs 14.5%, respectively), while that of patients with cirrhosis (28.2% vs 22.4%) and treatment-experienced patients (31.2% vs 27.1%) decreased. Among patients whose treatment outcome was known by 2016, high cure rates were observed, with an overall sustained virological response rate of 93.2%. From 2015 to 2016, there was a progressive increase in the proportion of treated patients who were non-cirrhotic, with current IVDU and non-liver transplant recipients.Conclusions The characteristics of patients with HCV remaining in contact with specialised care evolved with a changing landscape of treatment and related health policy. With increasing access to DAAs in UK, high cure rates were achieved in the study cohort.https://bmjopen.bmj.com/content/9/8/e029066.full |
| spellingShingle | Jason Gordon Anna Maria Geretti Lynsey Corless Laure Lacoin Michael Hurst Nathan R Hill Richard Aspinall Yuxiang Gao-Du Liam Mistry David Mutimer Evolution of the burden of active hepatitis C virus infection in England from September 2015 to September 2016: a repeated cross-sectional analysis BMJ Open |
| title | Evolution of the burden of active hepatitis C virus infection in England from September 2015 to September 2016: a repeated cross-sectional analysis |
| title_full | Evolution of the burden of active hepatitis C virus infection in England from September 2015 to September 2016: a repeated cross-sectional analysis |
| title_fullStr | Evolution of the burden of active hepatitis C virus infection in England from September 2015 to September 2016: a repeated cross-sectional analysis |
| title_full_unstemmed | Evolution of the burden of active hepatitis C virus infection in England from September 2015 to September 2016: a repeated cross-sectional analysis |
| title_short | Evolution of the burden of active hepatitis C virus infection in England from September 2015 to September 2016: a repeated cross-sectional analysis |
| title_sort | evolution of the burden of active hepatitis c virus infection in england from september 2015 to september 2016 a repeated cross sectional analysis |
| url | https://bmjopen.bmj.com/content/9/8/e029066.full |
| work_keys_str_mv | AT jasongordon evolutionoftheburdenofactivehepatitiscvirusinfectioninenglandfromseptember2015toseptember2016arepeatedcrosssectionalanalysis AT annamariageretti evolutionoftheburdenofactivehepatitiscvirusinfectioninenglandfromseptember2015toseptember2016arepeatedcrosssectionalanalysis AT lynseycorless evolutionoftheburdenofactivehepatitiscvirusinfectioninenglandfromseptember2015toseptember2016arepeatedcrosssectionalanalysis AT laurelacoin evolutionoftheburdenofactivehepatitiscvirusinfectioninenglandfromseptember2015toseptember2016arepeatedcrosssectionalanalysis AT michaelhurst evolutionoftheburdenofactivehepatitiscvirusinfectioninenglandfromseptember2015toseptember2016arepeatedcrosssectionalanalysis AT nathanrhill evolutionoftheburdenofactivehepatitiscvirusinfectioninenglandfromseptember2015toseptember2016arepeatedcrosssectionalanalysis AT richardaspinall evolutionoftheburdenofactivehepatitiscvirusinfectioninenglandfromseptember2015toseptember2016arepeatedcrosssectionalanalysis AT yuxianggaodu evolutionoftheburdenofactivehepatitiscvirusinfectioninenglandfromseptember2015toseptember2016arepeatedcrosssectionalanalysis AT liammistry evolutionoftheburdenofactivehepatitiscvirusinfectioninenglandfromseptember2015toseptember2016arepeatedcrosssectionalanalysis AT davidmutimer evolutionoftheburdenofactivehepatitiscvirusinfectioninenglandfromseptember2015toseptember2016arepeatedcrosssectionalanalysis |